



## **Description: Scholarship Competition – Entrepreneurship in Oncology and Life Science (CEO)**

### CONTEXT

It's with great enthusiasm that IRICoR launch the seventh edition of the Scholarship Competition – Entrepreneurship in Oncology (CEO), offering the next generation of scientists an opportunity to develop their entrepreneurial skills, along with their academic skills. Thus, IRICoR will offer training scholarships, as part of the [Life Sciences Entrepreneurship Development Program](#), created through a partnership between Montréal InVivo, Université de Montréal's Faculty of Pharmacy and Concordia University's John Molson Executive Centre, in collaboration with TransMedtech and IRICoR.

### WHY TAKE PART IN THE PROGRAM?

This practical and immersive training, the result of a joint effort between key players in life sciences from both industry and academia, will allow you to familiarize yourself with the development stages of an innovative company, from the lab to the market, through current management models that apply to both the research and the commercialization of innovation stages.

### BRIEF OVERVIEW

- The program includes 10 classroom intensive 2/3-day modules from October 2024 to June 2025, in order to allow you to gradually apply the knowledge acquired to the challenges you face on a daily basis.
- Furthermore, by taking part in this seventh cohort limited to about twenty candidates, you will be contributing to the progression of a tangible project with other participants from various backgrounds, thus allowing you to forge links with different players in the life science sector.

For more information, go to:

<https://www.concordia.ca/jmsb/executive-education/expertise/health-management/life-sciences-entrepreneurship-development.html>

### OBJECTIVE OF THE CEO COMPETITION

IRICoR wants to ensure the training of the next generation of scientists through better tools for project management and entrepreneurial skills. IRICoR aims to identify the most promising candidates in the ecosystem and make it easier for them to get a training that meets their needs.

### ELIGIBILITY OF APPLICANTS

Master (from the second year), PhD candidates, Postdoctoral Fellows and Young Investigators (max 10 years in position) affiliated with a Canadian teaching or research institution, at the time of application submission, are eligible.



### SCHOLARSHIP AMOUNT

The scholarship amount awarded to each recipient will cover the full program registration fees, namely \$7,500.

### FILLING OUT AND SENDING THE FORM

- Make sure to download and save the document onto your computer in order to fill it out.
- Please title the document as follows: *Last name\_application\_form\_CEO*, and then send it to [audrey.segret@umontreal.ca](mailto:audrey.segret@umontreal.ca), by **October 1<sup>st</sup> 2024**, 5:00pm.
- The document must be sent in .pdf format.

### APPLICANT'S COMMITMENT

By submitting his/her application, the applicant must agree:

- To attend all sessions of the Life Sciences Entrepreneurship Development Program.
- Following completion of the program, to provide IRICoR with his/her assessment of said program and of the competition; this assessment to be done when and how IRICoR deem fit (e.g. meeting, report, form, etc.).
- To authorize IRICoR to keep and to use all of the information contained in its file provided that all personal information will remain confidential.

For more information about the Life Sciences Entrepreneurship Development Program, please contact:

Valérie Lancelot-Mingot  
Programs Manager  
John Molson School of Business  
514 848-3960  
[valerie.lancelot-mingot@concordia.ca](mailto:valerie.lancelot-mingot@concordia.ca)

### About the Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR)

As a project maturation cluster in the field of drug discovery, IRICoR is a not-for-profit organization based at the Institute for Research in Immunology and Cancer (IRIC) of Université de Montréal. IRICoR's mandate is to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since 2008, IRICoR has successfully combined industry-standard business expertise and cutting-edge research. IRICoR invests in and supports particularly innovative selected projects, ensuring an effective transition of fundamental research into innovative therapies, through either co-development partnerships with the biopharmaceutical industry or the creation of spin-off companies. IRICoR provides selected academic and industry projects with access to its drug discovery network of experts and infrastructure, including one of the largest academia-based medicinal chemistry groups in Canada. IRICoR's major funding sources for the 2018-2023 period include the Canadian government's Centre of Excellence for Commercialization and Research (CECR) program, Québec government's programs through the *Ministère de l'Économie, de la Science et de l'Innovation* (MESI), and collaborative partnerships with the biopharmaceutical industry. For more information about IRICoR, go to: [iricor.ca](http://iricor.ca)